31293-71-7

Basic information

• Product Name: 1-Butanone,4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-phenyl-
• Synonyms: Butyrophenone,4-[4-(p-chlorophenyl)-4-hydroxypiperidino]- (6CI,7CI,8CI); R 1532
• CAS NO: 31293-71-7
• Molecular Formula: C21H24 Cl N O2
• Molecular Weight: 357.88
• Mol File: 31293-71-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-Butanone,4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Butanone,4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-phenyl-(31293-71-7)
• EPA Substance Registry System: 1-Butanone,4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-phenyl-(31293-71-7)

Safety Data

• Hazardous Substances Data: 31293-71-7(Hazardous Substances Data)

Usage

Chemical class

Piperidinyl phenyl compounds

Derivative of

4-Phenyl-1-piperidinyl butanone

Structural feature

Chlorophenyl group attached to the 4-position of the piperidine ring

Potential applications

Pharmaceutical industry

Biological activities

Not specified, but implied to have some

Health hazards

Potential health hazards, should be handled with care and proper safety protocols

Molecular weight

Not provided, but can be calculated from the chemical formula

Physical state

Not specified, but likely a solid or liquid at room temperature

Solubility

Not specified, but may be soluble in organic solvents due to its nonpolar nature

Stability

Not specified, but may be sensitive to heat, light, or moisture

Reactivity

Not specified, but may react with strong acids, bases, or nucleophiles

Synthesis

Not provided, but likely involves a multi-step process involving the formation of the piperidine ring and subsequent functional group modifications

Purity

Not specified, but should be assessed for pharmaceutical applications

Storage conditions

Not specified, but should be stored in a cool, dry, and dark place, away from incompatible substances

Regulatory status

Not specified, but may be subject to regulatory controls depending on its intended use and classification

Environmental impact

Not specified, but should be considered when handling and disposing of the compound

Disposal methods

Not specified, but should follow proper waste disposal protocols to minimize environmental impact

Synonyms

Not provided, but may have alternative names or trade names in the chemical industry

Upstream product

• 39512-49-7 4-(4-chlorophenyl)-4-hydroxypiperidine 
• 939-52-6 4-chloro-1-phenylbutan-1-one 
• 3308-98-3 2-(3-chloropropyl)-2-phenyl-[1,3]dioxolane 
• 71-43-2 benzene 
• 106-39-8 bromochlorobenzene 

Relevant articles and documents

Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from: Mycobacterium tuberculosis to overcome kanamycin resistance

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a deadly bacterial disease. Drug-resistant strains of Mtb make eradication of TB a daunting task. Overexpression of the enhanced intracellular survival (Eis) protein by Mtb confers resistance to the second-line antibiotic kanamycin (KAN). Eis is an acetyltransferase that acetylates KAN, inactivating its antimicrobial function. Development of Eis inhibitors as KAN adjuvant therapeutics is an attractive path to forestall and overcome KAN resistance. We discovered that an antipsychotic drug, haloperidol (HPD, 1), was a potent Eis inhibitor with IC50 = 0.39 ± 0.08 μM. We determined the crystal structure of the Eis-haloperidol (1) complex, which guided synthesis of 34 analogues. The structure-activity relationship study showed that in addition to haloperidol (1), eight analogues, some of which were smaller than 1, potently inhibited Eis (IC50 ≤ 1 μM). Crystal structures of Eis in complexes with three potent analogues and droperidol (DPD), an antiemetic and antipsychotic, were determined. Three compounds partially restored KAN sensitivity of a KAN-resistant Mtb strain K204 overexpressing Eis. The Eis inhibitors generally did not exhibit cytotoxicity against mammalian cells. All tested compounds were modestly metabolically stable in human liver microsomes, exhibiting 30-60% metabolism over the course of the assay. While direct repurposing of haloperidol as an anti-TB agent is unlikely due to its neurotoxicity, this study reveals potential approaches to modifying this chemical scaffold to minimize toxicity and improve metabolic stability, while preserving potent Eis inhibition. This journal is

Antifungal Compositions

Provided herein are antifungal compositions and methods of use thereof. The antifungal compositions include an antifungal agent and an antipsychotic agent or an antihistamine. The methods of use thereof include administering a composition including an antifungal agent and an antipsychotic or an antihistamine to a plant or animal in need thereof.